What is UroGen Pharma's operating lease liabilities?

UroGen Pharma (URGN) reported operating lease liabilities of -$53K in Q1 2026.

How has UroGen Pharma's operating lease liabilities changed year-over-year?

UroGen Pharma's operating lease liabilities increased by 92.8% year-over-year, from -$738K to -$53K.

What is the long-term trend for UroGen Pharma's operating lease liabilities?

Over 2 years (2022 to 2024), UroGen Pharma's operating lease liabilities has grown at a -4.1% compound annual growth rate (CAGR), from -$1.13M to -$1.03M.

UroGen Pharma URGN Operating lease liabilities

Operating lease liabilities at other companies

ImmunomeIMNM

——

TG TherapeuticsTGTX

——

Other financials

Income statement

See full

Revenue$51.0M+152%

Gross profit$11.6M—

Operating income-$22.8M—

Net income-$23.6M+46.2%

EPS (diluted)-$1.17—

Balance sheet

See full

Cash & equivalents$110.0M+5.7%

Total debt$197.1M+56.0%

Total equity-$124.3M-167%

Total assets$253.7M+2.5%

Cash flow

See full

Operating cash flow-$45.3M-7.8%

CapEx$54.0K+22.7%

Free cash flow-$45.4M-7.8%

Valuation

See full

Market cap$1.73B+71.7%

Enterprise value$1.81B+80.9%

P/S12.3×+1.3×

Profitability

See full

Gross margin89.7%—

Operating margin-329.7%—

Net margin-94.8%-25.6pp

FCF margin-118.2%+1.3pp

Returns & leverage

See full

Return on equity-211.6%—

Debt / equity4.8×—

Current ratio4.7×-1.0×

Where this comes from

Reported directly by UroGen Pharma in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: UroGen Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about UroGen Pharma's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is UroGen Pharma's operating lease liabilities?: UroGen Pharma (URGN) reported operating lease liabilities of -$53K in Q1 2026.
How has UroGen Pharma's operating lease liabilities changed year-over-year?: UroGen Pharma's operating lease liabilities increased by 92.8% year-over-year, from -$738K to -$53K.
What is the long-term trend for UroGen Pharma's operating lease liabilities?: Over 2 years (2022 to 2024), UroGen Pharma's operating lease liabilities has grown at a -4.1% compound annual growth rate (CAGR), from -$1.13M to -$1.03M.